Anagrelide and Apixaban: Interaction Details

Brand names
Anagrelide
Agrylin
Apixaban
EliquisELIQUIS 30-Day Starter PackEliquis Sprinkle
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Apixaban

Brand names
  • Eliquis
  • ELIQUIS 30-Day Starter Pack
  • Eliquis Sprinkle

What Happens When You Take Anagrelide With Apixaban

What can happen when they are taken together (rated Major)

Increased risk of bleeding and can cause serious, potentially fatal bleeding

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

The risk of bleeding rises when apixaban is given together with agents.2 In patients receiving an alongside an antiplatelet drug, any sign or symptom of blood loss should be assessed without delay.3

Patients should be informed about the signs and symptoms of blood loss and instructed to report them right away or to present to an emergency room. Apixaban should be stopped in any patient with active pathological , a point the source states twice.

A reversal agent for the anti-factor Xa activity of apixaban is available. The effect of apixaban is expected to last for no less than 24 hours following the final dose.

Options that may be considered include prothrombin complex concentrate (PCC), activated prothrombin complex concentrate, or recombinant factor VIIa. If PCCs are administered, tracking the anticoagulant effect of apixaban through a clotting test (PT, , or aPTT) or through anti-factor Xa (FXa) activity is not useful and is not recommended. Activated oral charcoal decreases the of apixaban and in turn reduces its .2

The Anagrelide and Apixaban Interaction, Explained

Anagrelide (Agrylin) lowers the number of in your blood, and at higher doses it can also make platelets less sticky. Platelets are the cells that help plug a cut. Apixaban (Eliquis) is a that slows down clotting proteins. Each one affects how your blood clots in a different way, so taking both together can raise your chance of bleeding. In rare cases that bleeding can be serious.

This concern is based mostly on how the drugs work, not on large studies. Many people take both safely when their care team is watching. Keep taking your medicines as prescribed, and talk with your pharmacist or doctor about any questions. Your team can monitor you closely and tailor your treatment.

Mechanism: effects on hemostasis. Anagrelide reduces count (megakaryocyte maturation ) and has activity via PDE3 inhibition. Apixaban is a direct factor Xa . No significant PK interaction is expected. Neither drug requires metabolic activation.

Effect: Increased bleeding risk, potentially serious or fatal. Onset unspecified. Evidence: theoretical, extrapolated from apixaban plus antiplatelet data. Severity: major.

  • Assess bleeding risk before combining therapy. Promptly evaluate signs of blood loss (Hgb/Hct, occult bleeding).
  • Discontinue apixaban for active pathological . Andexanet alfa reverses anti-FXa activity. Consider PCC, aPCC, or rFVIIa. Apixaban PD effect persists for 24 hours or more after the last dose.
  • PT, , aPTT, and anti-FXa are not useful after PCC use. Activated charcoal reduces apixaban .

See the 3 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Anagrelide and Apixaban Interact

The likely mechanism

effects on hemostasis

In short: Anagrelide and apixaban both make bleeding more likely, so taken together the effect can add up.
How Drug Interactions Work See this kind of interaction drawn out, step by step, in “When Effects Add Up or Cancel Out”, one chapter of our one-minute explainer. See how it works 

How to Manage the Anagrelide and Apixaban Interaction

When these two medicines are used together, your care team usually manages it by watching you more closely for bleeding. If bleeding happens, they can quickly check it and treat it.

  • Keep taking both medicines exactly as prescribed. Do not stop either one on your own.
  • Learn the signs of bleeding: unusual bruising, nosebleeds or bleeding gums that won't stop, pink, red, or brown urine, red or black stools, coughing or vomiting blood, or a severe headache.
  • Report these signs to your doctor right away. If the bleeding is serious, go to an emergency room.
  • Ask your pharmacist before taking other products that can increase bleeding, such as aspirin or ibuprofen.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Anagrelide or Apixaban need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

3 reports from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: ELIQUIS oral film coated tablets, apixaban oral film coated tablets

    APPRAISE-2, a clinical trial enrolling high-risk patients after acute coronary syndrome who were treated with aspirin or with aspirin plus clopidogrel, was stopped early because bleeding occurred at a higher rate with apixaban than with placebo. Among patients on single therapy, ISTH major bleeding occurred at 2.8% per year with apixaban compared with 0.6% per year with placebo; among those on dual antiplatelet therapy, the corresponding rates were 5.9% per year with apixaban and 2.5% per year with placebo.2

  2. Report 2 · Study title

    Prescribing information: ELIQUIS oral film coated tablets, apixaban oral film coated tablets

    In the ARISTOTLE clinical trial, among patients treated with apixaban, of aspirin raised the bleeding risk from 1.8% per year to 3.4% per year, and coadministration of aspirin and warfarin raised the bleeding risk from 2.7% per year to 4.6% per year. Use of dual therapy together with apixaban was limited (2.3%) in this trial.2

  3. Report 3 · Study title

    Direct oral anticoagulant plus antiplatelet therapy: prescribing practices and bleeding outcomes

    In a retrospective study, combining direct oral (DOAC) therapy with therapy (APT; n=78), compared with DOAC therapy alone (n=329), did not significantly change the incidence of major bleeding (1.3% vs 1.2%) or clinically relevant non-major bleeding (10.2% vs 6.4%) during 6 months of treatment. Most patients were Caucasian men, and the mean age was 63.7 years.

    Compared with those prescribed DOAC monotherapy, patients receiving concurrent APT had a significantly higher mean body mass index (30.7 vs 28.4) and mean CHA2DS2-VASc score (4.28 vs 3.85), and diabetes was more common among them (26.9% vs 17.3%). DOACs, prescribed for VTE treatment or atrial fibrillation, consisted of apixaban (58.5%), rivaroxaban (38.1%), and dabigatran (3.4%).

    Single antiplatelet therapy was used in 94.9% (74 patients), and the most frequent regimen was aspirin 81 mg once daily (69 patients). The remaining APT regimens were aspirin 81 mg twice daily (3 patients), aspirin 325 mg daily (1 patient), clopidogrel 75 mg daily (1 patient), and dual APT with aspirin 81 mg and clopidogrel 75 mg daily (4 patients).1

Anagrelide and Apixaban: Common Questions

How serious is the Anagrelide and Apixaban interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Anagrelide and Apixaban interaction managed?

When these two medicines are used together, your care team usually manages it by watching you more closely for bleeding. If bleeding happens, they can quickly check it and treat it. Keep taking both medicines exactly as prescribed. Do not stop either one on your own. Learn the signs of bleeding: unusual bruising, nosebleeds or bleeding gums that won't stop, pink, red, or brown urine, red or black… Management is individual — always follow your own care team's guidance.

How far apart should I take Anagrelide and Apixaban?

The interaction record says to take apixaban at least 24 hours after anagrelide.

Your pharmacist can help you fit this into the times you take your other medicines.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

Ask About the Anagrelide and Apixaban Interaction

Ask in your own words about taking Anagrelide and Apixaban together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (3)

  1. Tinkham TT, Vazquez SR, Jones AE, et al: Direct oral anticoagulant plus antiplatelet therapy: prescribing practices and bleeding outcomes. J Thromb Thrombolysis 2020; 49(3):492-496. PubMed
  2. Product Information: ELIQUIS(R) oral film coated tablets, apixaban oral film coated tablets. Bristol-Myers Squibb Company (per Dailymed), Princeton, NJ, 2024. DailyMed
  3. Product Information: SAVAYSA(R) oral tablets, edoxaban oral tablets. Daiichi Sankyo Inc (per FDA), Basking Ridge, NJ, 2023. DailyMed
Was this write-up helpful?

Other Serious Interactions of Anagrelide and Apixaban

Also serious with Anagrelide

Also serious with Apixaban

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Anagrelide

With Apixaban

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.